摘要
目的：探讨细胞因子诱导的杀伤细胞（CIK）治疗晚期胰腺癌的临床疗效与安全性。方法：收集2012年1月至2013年12月在我院住院治疗的74例晚期胰腺癌患者（Ⅲ～IV期），按随机数字表法将患者随机分为CIK细胞组（38例）和单纯化疗组（36例）。CIK细胞治疗组给予自体CIK细胞输注治疗，单纯化疗组仅用吉西他滨治疗，观察两组治疗前后近期疗效、中期疗效和安全性。结果：CIK细胞治疗组有效率为29．0％，与单纯化疗组16．7％差异无统计学意义（P〉0．05）；疾病控制率为63．2％，高于单纯化疗组38．9％（P〈0．05）；无进展生存时间（PFS）为3个月（95％CI：2．5—3．5），总生存时间（os）为6．8个月（95％CI：6．1-7．5），6个月生存率为41．7％，与单纯化疗组相比，差异有统计学意义（P〈0．05）。结论：CIK细胞治疗晚期胰腺癌安全可行．能够提高疾病控制率．改善患者免疫力并产生临床获益．
Objective To investigate the clinical efficacy and safety of the cytokine-induced killer cells （CIK） treated in patients with advanced pancreatic cancer. Methods 74 cases （hospitalized from January 2012 to December 2013 ） with advanced pancreatic cancer .（ Ⅱ - Ⅳ stage） were selected. The patients were randomly divided into two groups： CIK cells treated group （38 patients） and chemotherapy group （36 cases）. Patients in CIK cells group received CIK cell infusion therapy, and patients in chemotherapy group received only gemcitabine. The efficacy and safety of all patients were observed. Results The efficacy rate of CIK cells group was 29.0%, with no statistical significance compared to chemotherapy alone group （16.7%）. Disease control rate was 63.2%, with statistical significance compared to the chemotherapy group （38.9%）. The P17S was 3 months （95%CI：2.5 - 3.5）, OS 6.8 months （95%CI：6.1 - 7.5）. 6-month survival rate 41.7%, with statistically significance compared to chemotherapy group. Conclusion CIK cells treated in patients with advanced pancreatic cancer is feasible and safe, and can improve disease control rate, improve immunity and produce clinical benefit in patients.
出处
《实用医学杂志》
CAS
北大核心
2015年第13期2148-2151,共4页
The Journal of Practical Medicine
